系统性红斑狼疮起始队列中抗磷脂抗体轨迹与临床关联
在INSPIRE注册的前瞻性起始队列中,270例新诊断SLE患者(中位病程232天)于基线、6和24个月检测aPL。77.1%至少一次aPL阳性,以低滴度为主;双/三阳性与持续阳性相关,3.1%从阴性/低滴度进展为高风险谱。两年内7%发生血栓,高风险和持续阳性组风险更高,持续阴性者无血栓。
要点
- 早期SLE中aPL多为低滴度且波动,部分患者可演变为高风险谱。
- 双/三阳性与aPL持续阳性相关,持续阴性者两年内无血栓事件。
- aPL滴度与SLEDAI-2K或PGA不相关,支持系列aPL检测。
核心结论
- 早期SLE中aPL大多为低滴度且波动,部分患者可进展为更高风险状态,支持系列aPL检测。
研究设计与样本
- 在INSPIRE注册内开展的前瞻性研究,纳入新诊断SLE患者270例,中位病程232天(114-484),于基线、6和24个月采集血清。
- 采用ELISA检测抗心磷脂(aCL)和抗β2糖蛋白I(anti-β2GPI)IgG/IgM,条件允许时检测狼疮抗凝物。
主要发现
- 270例中77.1%至少一次aPL阳性,以低滴度为主;中高滴度aPL较少见且稳定。
- 基线阴性或低滴度/单阳性者多数转阴,双或三阳性与持续阳性相关;3.1%从阴性/低滴度进展为高风险谱。
- aPL转阴发生于12.5%,与基线aPL负荷呈负相关。
- 两年内19例(7%)发生血栓,高风险组和持续阳性组风险更高;持续aPL阴性者无血栓事件。
- aPL滴度与SLEDAI-2K或PGA不相关,aCL IgG和anti-β2GPI IgG与抗dsDNA弱相关;各组SDI均保持低水平。
关键数值与推荐
- aPL阳性采用制造商cut-off分析,中高滴度定义为>40 U。
- 按EULAR推荐定义高风险和低风险aPL谱。
- 患者分为持续阴性、持续阳性、波动和转阴四类。
临床怎么用
- 对早期SLE患者应系列检测aPL以识别向高风险谱的演变。
- 持续aPL阴性者血栓风险较低,高风险和持续阳性者需加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate longitudinal antiphospholipid antibody (aPL) patterns in newly diagnosed systemic lupus erythematosus (SLE) and their association with vascular events, disease activity and organ damage. METHODS: We conducted a prospective study within the INSPIRE registry including patients with newly diagnosed SLE (median disease duration 232 days [114-484]) with serum at baseline, 6 and 24 months. Anti-cardiolipin (aCL) and anti-beta2 glycoprotein I (anti-β2GPI) IgG/IgM were measured by ELISA; lupus anticoagulant when feasible. aPL positivity was analysed using manufacturer cut-offs and moderate-high titres (>40 U). Patients were classified as persistently negative, positive, fluctuating or negativised. High- and low-risk aPL profiles were defined per EULAR recommendations. Associations with thrombosis, SLEDAI-2K, Physician Global Assessment (PGA) and SLICC/ACR Damage Index (SDI) were assessed. RESULTS: Among 270 patients, 77.1% were aPL-positive at least once, predominantly low-titre. Moderate-high titre aPLs were less frequent and stable. Most patients with baseline negativity or low-titre/single positivity reverted to negative, whereas dual or triple positivity was associated with persistence. A subgroup (3.1%) progressed from negative/low-titre to high-risk profiles. aPL negativisation occurred in 12.5% and was inversely associated with baseline aPL burden. Over two years, 19 (7%) developed thrombosis, with higher risk in high-risk and persistently positive groups; no thrombotic events occurred in persistently aPL-negative patients.aPL titres did not correlate with SLEDAI-2K or PGA, while aCL IgG and anti-β2GPI IgG correlated weakly with anti-dsDNA. SDI remained low across groups. CONCLUSION: In early SLE, aPLs are largely low-titre and fluctuating, with some patients evolving to higher-risk states, supporting serial aPL testing.
引用
- Mishra RK, Kavadichanda C, Baskaran P, et al. Antiphospholipid antibody trajectories and clinical correlates in an inception cohort of systemic lupus erythematosus. Rheumatology (Oxford). 2026. PMID: 42568146. doi:10.1093/rheumatology/keag407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。